Auto Amazon Links: No products found. Blocked by captcha.
In a groundbreaking head-to-head trial of two prominent weight-loss medications, Mounjaro has emerged as the more effective option when compared to its rival, Wegovy. The trial results revealed that both drugs resulted in significant weight loss, with Mounjaro leading to a 20% reduction in weight after 72 weeks of treatment, surpassing Wegovy’s 14% reduction.
The researchers leading the trial noted that both drugs play a role in weight loss, but Mounjaro may be particularly beneficial for individuals with a significant amount of weight to lose. While both medications aim to induce a feeling of fullness in the brain to curb appetite and promote fat burning, subtle differences in their mechanisms of action account for variations in their efficacy.
Wegovy, also known as semaglutide, mimics a post-meal hormone to activate one appetite switch in the brain, whereas Mounjaro, or tirzepatide, targets two switches. The trial, which involved 750 obese individuals with an average weight of 113kg, showcased Mounjaro’s superiority over Wegovy in terms of weight loss, waistline reduction, and improvements in blood pressure, blood sugar, and cholesterol levels.
Private sales of tirzepatide have reportedly outpaced semaglutide in the UK, signaling a growing interest in effective weight-loss medications among consumers. While both drugs offer viable options for patients, ongoing research aims to explore higher doses, alternative delivery formats like oral pills, and novel compounds with varying modes of action to address weight management. As the quest for the ultimate weight-loss medication continues, the landscape of obesity treatment and prevention stands to evolve significantly in the near future
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.